Apolipoprotein B in cardiovascular risk assessment
Maud Ahmad, Allan D. Sniderman, Robert A. Hegele
Abstract
The 2021 Canadian Cardiovascular Society guideline on dyslipidemia recommends that physicians may use levels of either non-high-density lipoprotein cholesterol (HDL-C) or apo B instead of LDL-C for screening and targets of treatment.[1][1] Non-HDL-C represents total cholesterol minus cholesterol
Topics & Concepts
DyslipidemiaGuidelineApolipoprotein BCholesterolMedicineLdl cholesterolHigh-density lipoproteinInternal medicineLipoproteinEndocrinologyBioinformaticsBiologyPathologyObesityLipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and LipoproteinsCancer, Lipids, and Metabolism